In diabetic mice, SGLT2 inhibitors reduced albuminuria by ameliorating intraglomerular hypertension and tubulointerstitial fibrosis73,74, which are the two key contributors to renal damage in diabetic kidney disease (DKD). Here, SLC5A2 is linked to hypertensive disorder.